Affiliation:
1. Medical College, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
2. The First Affiliated Hospital of Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
3. Institute of Biomedicine and Department of Cellular Biology, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
4. Hangzhou Iron and Steel Company Worker Hospital, 1 Kangjian Road, Gongye Area, Hangzhou, Zhejiang 310022, China
Abstract
Purpose.To evaluate the therapeutic effectiveness and safety of shenqi fuzheng injection (SFI) in the associated chemotherapy of breast cancer.Methods. 1247 subjects were included in this study for meta-analysis with RevMan 5.3.Results. The clinical curative effective rate (OR = 2.03, 95% Cl [1.44, 2.86],P<0.0001), grades of KPS (OR = 4.11, 95% Cl [2.74, 6.16],P<0.00001), CD3+cells (MD = 7.05, 95% Cl [0.45, 13.64],P=0.04) and CD4+cells (MD = 8.60, 95% Cl [2.67, 14.54],P=0.004) and CD4/CD8+cells (MD = 0.35, 95% Cl [0.14, 0.56],P=0.001), WBC (OR = 0.30, 95% Cl [0.20, 0.46],P≤0.0001), PLT (OR = 0.36, 95% Cl [0.20, 0.67],P=0.001), gastrointestinal reaction (OR = 0.21, 95% Cl [0.14, 0.32],P<0.00001), and ECG (OR = 0.26, 95% Cl [0.13, 0.51],P<0.0001) in the experimental group were superior to the control group. While there were no differences between two groups in CD8+(MD = 0.21, 95% Cl [−2.81, 3.23],P=0.89), NK+(MD = 1.06, 95% Cl [−9.40, 11.53],P=0.84), RBC (OR = 0.49, 95% Cl [0.14, 1.74],P=0.27), liver function (OR = 0.59, 95% Cl [0.28, 1.24],P=0.16), renal function (OR = 0.56, 95% Cl [0.13, 2.45],P=0.44), and bone marrow suppression (OR = 0.50, 95% Cl [0.25, 1.01],P=0.05).Conclusion. SFI combined with chemotherapy, to some extent, can improve the effectiveness and the security in the treatment of breast cancer; the mechanism may be related to the elevated immunity.
Funder
National Natural Science Foundation of China
Subject
Complementary and alternative medicine